Table 1.
Echocardiographic data
| 0 (Pre-DM induction) | 4 weeks (Pre-treatment) | 6 weeks (2 weeks after treatment) | 8 weeks (4 weeks after treatment) | |
|---|---|---|---|---|
| FS (%) | ||||
| Control | 47.0 ± 3.6 | 49.8 ± 3.5 | 50.9 ± 2.7 | 48.8 ± 2.1 |
| Untreated DMCM | 46.3 ± 2.2 | 38.8 ± 2.3 | 37.9 ± 2.7 | 35.1 ± 3.0 |
| Treated DMCM | 46.3 ± 3.1 | 39.5 ± 2.2 | 42.7 ± 3.3 | 42.6 ± 3.5 |
| Group effect: P < 0.0001; time effect: P < 0.0001; interaction group × time effect: P < 0.0001 | ||||
| LVEDD (mm) | ||||
| Control | 6.338 ± 0.497 | 6.477 ± 0.481 | 6.711 ± 0.276 | 6.694 ± 0.359 |
| Untreated DMCM | 6.471 ± 0.456 | 7.173 ± 0.327 | 7.705 ± 0.341 | 7.965 ± 0.320 |
| Treated DMCM | 6.273 ± 0.379 | 7.114 ± 0.414 | 7.405 ± 0.352 | 7.483 ± 0.635 |
| Group effect: P < 0.0001; time effect: P < 0.0001; interaction group × time effect: P < 0.05 | ||||
| LVEDD (mm) | ||||
| Control | 3.368 ± 0.449 | 3.262 ± 0.449 | 3.305 ± 0.268 | 3.427 ± 0.268 |
| Untreated DMCM | 3.477 ± 0.315 | 4.416 ± 0.306 | 4.786 ± 0.309 | 4.786 ± 0.362 |
| Treated DMCM | 3.373 ± 0.330 | 4.305 ± 0.348 | 4.242 ± 0.347 | 4.300 ± 0.550 |
| Group effect: P < 0.0001; time effect: P < 0.0001; interaction group × time effect: P < 0.0001 | ||||
Serial data for fraction shortening (%), left ventricle end-diastolic dimension (mm), and left ventricle end-systolic dimension (mm) were demonstrated
DM diabetes mellitus, DMCM diabetic cardiomyopathy, FS fraction shortening, LVEDD left ventricle end-systolic dimension, LVESD left ventricle end-systolic dimension